Drug Approval | November 14, 2025
Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Glenmark will begin distribution in November 2025
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Subscribe To Our Newsletter & Stay Updated
